Skip to main content

Interpace TERT biomarker

Interpace Diagnostics launched the TERT biomarker for ordering along with its ThyGenX molecular thyroid cancer test. The TERT marker is a molecular predictor of the aggressiveness of thyroid cancer, and the addition of it to the ThyGenX test will provide evidence that a positive result indicates the cancer is likely to be more aggressive in nature, the company said. Physicians can order the new marker as part of the ThyGenx mutation panel or on an individual basis. 

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.